Skip to main content

Table 2 . Incidence and Risk of hospitalisation for pneumococcal pneumonia, all-cause pneumonia and death from any cause in relation to PCV13 vaccination status in the total study population (N=2,025,730)

From: Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study

Event

Parameter

Pneumococcal pneumonia

All cause pneumonia

Death from any cause

Number of events

 Vaccinated

20

228

420

 Unvaccinated

1,628

12,471

46,845

Unadjusted incidence rate per 1000

person-years

   

 Vaccinated

289.3

3,298.6

5,944.0

  (95% CI)

(176.8-445.5)

(2,909.4-3,740.6)

(5,385.2-6,562.1)

 Unvaccinated

82.1

  

  (95% CI)

(77.1-87.4)

628.6

(590.3-668.8)

2,354.5

(2,210.9-2,505.2)

Unadjusted hazard ratio

3.70

5.44

2.51

 (95% CI)

(2.38-5.76)

(4.77-6.20)

(2.28-2.76)

 p value

<0.001

<0.001

<0.001

Age and sex adjusted hazard ratio

2.40

3.42

1.68

 (95% CI)

(1.55-3.74)

(3.00-3.89)

(1.53-1.85)

 p value

<0.001

<0.001

<0.001

Multivariable-adjusted hazard ratio

1.17a

1.69b

1.07c

 (95% CI)

(0.75-1.83)

(1.48-1.94)

(0.97-1.18)

 p value

0.493

<0.001

0.190

  1. NOTE: The hazard ratios are for PCV13 vaccinated subjects as compared with PCV13 unvaccinated subjects.
  2. aadjusted for age (continuous), sex, history of pneumococcal disease or pneumonia during the previous 24 months, presence of chronic pulmonary/respiratory disease, chronic heart disease, diabetes, chronic liver disease, alcoholism, current smoking, immunodeficiency, HIV infection, chronic renal disease, cancer, immunosuppressive therapy, history of pneumococcal polysaccharide vaccination at any time and receipt or non receipt of influenza vaccine in prior autumn.
  3. b adjusted for age (continuous), sex, history of pneumococcal disease or pneumonia during the previous 24 months, presence of chronic pulmonary/respiratory disease, chronic heart disease, diabetes, chronic liver disease, alcoholism, current smoking, immunodeficiency, HIV infection, chronic renal disease, bone marrow transplantation, cancer, immunosuppressive therapy, history of pneumococcal polysaccharide vaccination at any time and receipt or non receipt of influenza vaccine in prior autumn.
  4. cadjusted for age (continuous), sex, history of pneumococcal disease or pneumonia during the previous 24 months, presence of chronic pulmonary/respiratory disease, chronic heart disease, diabetes, chronic liver disease, alcoholism, current smoking, asplenia, immunodeficiency, HIV infection, chronic renal disease, bone marrow transplantation, cancer, immunosuppressive therapy, history of pneumococcal polysaccharide vaccination at any time and receipt or non receipt of influenza vaccine in prior autumn.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us